Nikko Asset Management Americas, Inc. Cellectis S.A. Transaction History

Nikko Asset Management Americas, Inc.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 06, 2022	SELL	$3.45 - $8.77 $2.17 Million - $5.51 Million	-627,910 Closed	0 $0
Q4 2021 Feb 08, 2022	SELL	$8.01 - $12.84 $548,564 - $879,347	-68,485 Reduced 9.83%	627,910 $5.4 Million
Q3 2021 Nov 09, 2021	SELL	$11.94 - $16.09 $1.08 Million - $1.46 Million	-90,488 Reduced 11.5%	696,395 $8.74 Million
Q2 2021 Aug 09, 2021	SELL	$14.36 - $20.93 $1.49 Million - $2.17 Million	-103,628 Reduced 11.64%	786,883 $12 Million
Q1 2021 May 03, 2021	BUY	$18.19 - $33.25 $2.12 Million - $3.88 Million	116,723 Added 15.08%	890,511 $18 Million
Q4 2020 Feb 11, 2021	BUY	$15.87 - $31.64 $1.61 Million - $3.2 Million	101,167 Added 15.04%	773,788 $20.9 Million
Q3 2020 Nov 02, 2020	SELL	$15.7 - $20.84 $873,877 - $1.16 Million	-55,661 Reduced 7.64%	672,621 $12.7 Million
Q2 2020 Aug 07, 2020	SELL	$8.21 - $21.02 $4.62 Million - $11.8 Million	-562,791 Reduced 43.59%	728,282 $12.7 Million
Q1 2020 Apr 30, 2020	BUY	$7.81 - $18.82 $93,142 - $224,447	11,926 Added 0.93%	1,291,073 $11.9 Million
Q4 2019 Feb 06, 2020	SELL	$9.73 - $19.31 $341,990 - $678,707	-35,148 Reduced 2.67%	1,279,147 $21.9 Million
Q3 2019 Oct 29, 2019	BUY	$10.15 - $16.89 $913,104 - $1.52 Million	89,961 Added 7.35%	1,314,295 $13.7 Million
Q2 2019 Jul 29, 2019	BUY	$14.6 - $20.6 $5.87 Million - $8.28 Million	401,888 Added 48.86%	1,224,334 $19.1 Million
Q1 2019 Apr 30, 2019	BUY	$15.53 - $19.75 $12.8 Million - $16.2 Million	822,446 New	822,446 $15.1 Million

11.2M

5.9K

1.4K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $78.7M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Nikko Asset Management Americas, Inc., based on Form 13F filings with the SEC.

Stay updated on Nikko Asset Management Americas, Inc. with notifications on news.